Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.

Julie Gralow, MD, FACP, FASCO, explains that a combination of the growing US population and the increasing rate of clinicians reporting burnout and retiring early are major factors contributing to the ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

The FDA has approved an investigational device exemption (IDE) application for the start of a pilot study evaluating the ...

Uday R. Popat, MD, discusses promising findings from a phase 2 trial evaluating the JAK inhibitor itacitinib combined with ...

Panelists discuss how, when a patient progresses to second-line therapy, key considerations include prior treatment response, toxicity, patient comorbidities, and therapeutic goals. Lenvatinib shows ...

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for ...

Marlise R. Luskin, MD, MSCE, discusses the vigilant monitoring required for capillary leak syndrome with tagraxofusp in BPDCN ...